Degludec

Type: Product
Name: Degludec
First reported 16 hours ago - Updated 12 hours ago - 1 reports

Novo Nordisk introduces Ryzodeg in Mexico for type 2 diabetes

Denmark-based Novo Nordisk has introduced Ryzodeg (insulin degludec/insulin aspart) in Mexico, which will be used to treat adult patients suffering from type 2 diabetes.The launch makes Mexico the first country in the world where Ryzodeg will be avai ... [Published Pharmaceutical Technology - 16 hours ago]
First reported 18 hours ago - Updated 18 hours ago - 1 reports

Novo Nordisk ends inflammatory R&D, sticks to diabetes

Novo Nordisk is pulling out of inflammatory disorder R&D to increase its diabetes and obesity efforts, following the failure of an investigational rheumatoid arthritis drug.The decision to discontinue comes after the Danish firm ended Phase II development ... [Published Pharma Times - 18 hours ago]
First reported Sep 01 2014 - Updated 20 hours ago - 6 reports

Novo Nordisk debuts diabetes combo in Mexico

Danish pharma company Novo Nordisk has not had the best of times with its diabetes pipeline of late, but chalked up a success with the first launch of its Ryzodeg combination insulin product in Mexico.Ryzodeg combines the long-acting basal insulin in ... [Published PMLive - 20 hours ago]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Insulin Market Heats Up as Biosimilars and Newer Forms Emerge

The US Food and Drug Administration (FDA) has issued a tentative approval for Lilly and Boehringer Ingelheim's insulin glargine product, to be called Basaglar , for use in adults with type 2 diabetes and both children and adults with type 1 d ... [Published General Medicine eJournal - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 3 reports

Novo Nordisk accepts Danish fine regarding late disclosure of FDA complete response letter for Tresiba, Ryzodeg

Novo Nordisk announced Monday that it agreed to pay a fine of 500 000 Danish kroner ($90 000) imposed by authorities in Denmark for failing to inform investors soon enough that the FDA had declined to approve its diabetes drugs Tresiba (insulin degludec) ... [Published FirstWord Pharma - Aug 18 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

CHMP positive opinion for Xultophy

Novo Nordisk has announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion for Xultophy, the first ever once-daily basal insulin (insulin degludec, Tresiba) and GLP-1 ... [Published European Pharmaceutical Manufacturer - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Sihuan (00460), Chongqing Biotech sign collaborative agt

AM (Infocast News) Sihuan Pharmaceutical Holdings Group Ltd. (00460) has entered into a collaborative development agreement with Chongqing Peg-Bio BioTechnology Co., Ltd (Chongqing Biotech), pursuant to which Chongqing Biotech agreed to collaborate with ... [Published CCB International - Aug 14 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 2 reports

Data demonstrates 'efficacy and tolerability' of IDegLira

A 'significantly greater glucose-lowering effect with IDegLira' has been shown.11 August, 2014 05:33 PMDiabetes Care has published phase IIIa findings that demonstrate a significantly greater glucose-lowering effect with IDegLira (insulin degludec/liraglutide; ... [Published Hospital Pharmacy Europe - Aug 12 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Added benefit of Novo Nordisk’s Tresiba not proven, says IQWiG

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether Danish diabetes care giant Novo Nordisk’s (NOV: ... [Published Pharma Letter - Aug 08 2014]
Entities: IQWiG, Insulin, Degludec
First reported Aug 07 2014 - Updated Aug 08 2014 - 2 reports

Novo Nordisk tops Q2 profit estimates, advances potential US launch of Tresiba

Novo Nordisk reported Thursday that second-quarter profit gained 4 percent year-on-year to 7 billion Danish kroner ($1.3 billion), beating the 6.9 billion kroner ($1.2 billion) analysts were expecting. Sales in the three-month period climbed 1 percent ... [Published FirstWord Pharma - Aug 07 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Transparency Issues Floor Novo Nordisk's Tresiba At IQWiG

MEPs Pass Clinical Trials Laws But Implementation Will Be Troublesome “The Pink Sheet” DAILY Apr. 3, 2014Novo Nordisk Withholding Tresiba From German HTA Process “The Pink Sheet” DAILY Aug. 20, 2013Novo Nordisk Dismayed By “Complete Response” ... [Published Health News Daily - Aug 05 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Novo Nordisk Diabetes Drug Xultophy (IDegLira) Gets Positive CHMP View

Xultophy, a type 2 diabetes candidate, received a positive opinion from the European Medicines Agency's Committee. Xultophy is a once-daily single injection combination of insulin degludec and liraglutide. The CHMP recommended the approval of Xultophy ... [Published Diabetes in Control - Aug 04 2014]

Quotes

Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard Thomsen said: "Ryzodeg is a new approach to diabetes management, and we are very pleased to make it available now for people with diabetes."
Dr. Lane says concentrated insulins are scoring highly on 1 scale, however. "Patients who were questioned after the switch to U500 expressed more content"
...assess the impacts of the complete response letter, in which the agency requested more data from a dedicated cardiovascular outcomes trial. "However, for resource reasons, [our] management has chosen to accept the fine to avoid a lengthy lawsuit" the company said, adding "this will finally settle the case."
...CEO Lars Rebien Sørensen said "this has enabled us to shorten further the timeline towards…a potential US launch of Tresiba" which he noted is "doing well in key markets."

More Content

All (51) | News (43) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Novo Nordisk introduces Ryzodeg in Mexico for t... [Published Pharmaceutical Technology - 16 hours ago]
Novo Nordisk ends inflammatory R&D, sticks to d... [Published Pharma Times - 18 hours ago]
Novo Nordisk debuts diabetes combo in Mexico [Published PMLive - 20 hours ago]
Novo Nordisk launches Ryzodeg in Mexico for peo... [Published PharmaBiz - Sep 02 2014]
Mexico first country to launch Novo Nordisk’s R... [Published Pharma Letter - Sep 01 2014]
Mexico first country to launch Ryzodeg® [Published European Pharmaceutical Review - Sep 01 2014]
Denmark's Novo Nordisk launches Ryzodeg in Mexico [Published Sharenet - Sep 01 2014]
Mexico first country to launch Ryzodeg® [Published Noodls - Sep 01 2014]
Mexico first country to launch Ryzodeg® [Published Novo Nordisk A/S - Press Releases - Sep 01 2014]
Health ministry to set up expert panel to re-ex... [Published PharmaBiz - Sep 01 2014]
diaTribe Presents at the FDA – A Public Hearing... [Published diaTribe - Aug 29 2014]
Insulin Market Heats Up as Biosimilars and Newe... [Published General Medicine eJournal - Aug 19 2014]
Novo Nordisk accepts Danish fine regarding late... [Published FirstWord Pharma - Aug 18 2014]
Novo accepts Denmark fine in Tresiba disclosure... [Published Pharma Times - Aug 18 2014]
Novo Nordisk to pay Danish fine for late disclo... [Published FirstWord Pharma - Aug 18 2014]
CHMP positive opinion for Xultophy [Published European Pharmaceutical Manufacturer - Aug 14 2014]
Sihuan (00460), Chongqing Biotech sign collabor... [Published CCB International - Aug 14 2014]
Novo Nordisk’s GLP-1/insulin combination, Xulto... [Published diaTribe - Aug 12 2014]
Data demonstrates 'efficacy and tolerability' o... [Published Hospital Pharmacy Europe - Aug 12 2014]
Positive new Ph III data with Novo Nordisk’s Xu... [Published Pharma Letter - Aug 11 2014]
Novo says Tresiba trial is ahead of schedule [Published MedNous - Aug 08 2014]
Added benefit of Novo Nordisk’s Tresiba not pro... [Published Pharma Letter - Aug 08 2014]
Novo Nordisk tops Q2 profit estimates, advances... [Published FirstWord Pharma - Aug 07 2014]
Novo Nordisk beats estimates as net profit grow... [Published Pharma Letter - Aug 07 2014]
Novo Nordisk A/S: Novo Nordisk increased operat... [Published EuroInvestor - Aug 07 2014]
Transparency Issues Floor Novo Nordisk's Tresib... [Published Health News Daily - Aug 05 2014]
Novo Nordisk Diabetes Drug Xultophy (IDegLira) ... [Published Diabetes in Control - Aug 04 2014]
AWMSG decisions [Published Pharmaceutical Journal - Jul 30 2014]
Novo Nordisk Diabetes Drug Xultophy Gets Positi... [Published Zacks.com - Jul 29 2014]
CHMP positive opinion for Xultophy? [Published Hospital Pharmacy Europe - Jul 28 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Mexico first country to launch Ryzodeg® [Published Novo Nordisk A/S - Press Releases - Sep 01 2014]
Bagsværd, Denmark, 1 September 2014 - Novo Nordisk today announced that in Mexico, as the first country in the world, Ryzodeg® is now launched and made available for people with type 2 diabetes. Ryzodeg® is a combination of two distinct insulin analogues ...
Novo Nordisk's Insulin Degludec/Liraglutide is ... [Published PR Newswire: General Business - Jul 07 2014]
BURLINGTON, Mass., July 7, 2014 /PRNewswire/ -- Decision Resources Group finds that Novo Nordisk's fixed-dose combination (FDC) therapy insulin degludec/liraglutide (Xultophy, formerly known as IDegLira) is set to become the clinical gold-standard ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jun 26 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jun 25 2014]
New One-year Data of IDegLira Shows Glucose-low... [Published PR Newswire: Health - Jun 14 2014]
SAN FRANCISCO, June 14, 2014 /PRNewswire/ --New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its glucose-lowering ...
1 2

Press Releases

sort by: Date | Relevance
Novo Nordisk A/S: Novo Nordisk receives positiv... [Published GlobeNewswire: Acquisitions News - Jul 25 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.